Prosecution Insights
Last updated: November 18, 2026
Application No. 19/009,634

LIVESTOCK HEART RATE MEASUREMENT WITH BOLUS SENSOR

Non-Final OA §102§112§DOUBLEPATENT
Filed
Jan 03, 2025
Priority
Jul 26, 2021 — divisional of 12/220,261
Examiner
ROBERTS, ANNA L
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
St Reproductive Technologies LLC
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
95%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
94 granted / 170 resolved
-14.7% vs TC avg
Strong +39% interview lift
Without
With
+39.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
60 currently pending
Career history
241
Total Applications
across all art units

Office Action

§102 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Objections Claims 1-2 and 4-5 are objected to because of the following informalities: Claim 1, line 2-3, “the animal sensor signal” should be “sensor signal”. Claim 1, lines 8-9 and 10 “motion sensor signal” should be “sensor signal”. Claim 2, line 3 “the sensor” should be “the motion sensor”. Claim 4, line 2-3 “the respiration-corrected linear magnitude component” should be “the respiration-corrected linear magnitude”. Claim 5, line 4-5 “the respiration-corrected linear magnitude component” should be “the respiration-corrected linear magnitude”. Claim 5, line 7-8 “the detecting of the animal heart signal through use of the second filtered linear magnitude component” should be “wherein the detecting of the animal heart signal uses the second filtered linear magnitude component” or similar. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 recites the limitation “the animal heart rate” in line 3 of the claim. There is insufficient antecedent basis for this limitation of the claim and as a result it is unclear if the limitation is intended to refer to a heart rate of the animal or the animal heart signal. The limitation is interpreted as referring to a heart rate of the animal. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-7 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 8-14, and 16 of U.S. Patent No. 12220261 in view of Rettedal (US 20200113481 A1). The reference patent claims teach all limitations of the claims except for the following limitations of claim 1: ii) a wireless connection for transmitting the sensor signal; and iii) at least one hardware processor programmed to perform operations. Rettedal, in the same field of endeavor of a system for monitoring an animal including a bolus sensor, teaches that a bolus sensor may include ii) a wireless connection for transmitting the sensor signal (Abstract, paragraph 0002, 0025-0026, 0051—the animal monitoring device (6) can further operate to generate and transmit a first radio frequency signal (13) (also referred to as a “first RF signal”) which can carry encoded animal identification information (12) and encoded sensed animal characteristic information (11)… an inert bolus (4) orally administrable to an animal (or implantable in an animal) (3) containing the AMD (6) which includes … a first radio frequency generator (87) including one or more of an oscillator (88), a radio frequency stabilizer (89), an antenna (90), and a power source (91) which operate to generate the first radio frequency signal (13); Fig. 4, ); and iii) at least one hardware processor programmed to perform operations (Paragraph 0025, 0028, 0051-- A microcontroller (7) having one or more processors (8) which operate to continuously or intermittently transform the analog or digital sensor signal (10) from the one or more sensors (9) to generate encoded sensed animal characteristic information (11)… an inert bolus (4) orally administrable to an animal (or implantable in an animal) (3) containing the AMD (6) which includes one or more of a microcontroller (7), one or more processors (8); Fig. 4). It would have been obvious to one having ordinary skill in the art at the time of filing to modify the reference patent claims, which disclose monitoring a motion sensor signal generated by an animal bolus sensor, to explicitly include a wireless connection and at least one processor within the animal bolus sensor, in order to predictably improve the system and method by enabling measurements performed by the sensor to be received wirelessly while the bolus sensor remains in place, rather than requiring extraction of the bolus sensor to observe measurements and additionally to enable a user to control the operation of the bolus sensor via an onboard processor which would allow for operation of the bolus sensor to be programmed rather than requiring direct operation of the sensor. Conclusion The claims are not presently rejected under 35 U.S.C. 102/103. The most pertinent prior art, Rettedal (US 20200113481 A1), Pless (US 20230053966 A1), and Dieken (US 20230119173 A1) teaches a bolus comprising: a motion sensor that generates a sensor signal, the animal sensor signal having a rotational component describing a rotation of the motion sensor within an animal and a linear component describing a linear movement of the motion sensor within the animal, a wireless connection for transmitting the sensor signal; and at least one hardware processor programmed to perform operations of identifying an animal respiration signal with the rotational component of the motion sensor signal. However, the prior art of the record fails to sufficiently teach and/or fairly suggest, in combination with all other recited limitations, “generating a respiration-corrected linear component through use of the linear component of the motion sensor signal and the animal respiration signal; and detecting an animal heart signal from the respiration-corrected linear component”. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNA ROBERTS whose telephone number is (571)272-7912. The examiner can normally be reached M-F 8:30-4:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at (571) 272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANNA ROBERTS/Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Jan 03, 2025
Application Filed
Aug 05, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788866
ALARMS AND ALERTS IN DIABETES MANAGEMENT SYSTEM
7y 11m to grant Granted Nov 10, 2026
Patent 12672825
DEVICES, SYSTEMS AND METHODS OF PELVIC FLOOR MUSCLE EXAMINATION
4y 0m to grant Granted Jul 07, 2026
Patent 12672826
USING A HEARABLE TO GENERATE A USER HEALTH INDICATOR BASED ON USER TEMPERATURE
3y 7m to grant Granted Jul 07, 2026
Patent 12667291
UROFLOWMETER
2y 4m to grant Granted Jun 30, 2026
Patent 12608083
WEARABLE DEVICE FOR PROVIDING HAPTIC FEEDBACK AND OPERATION METHOD THEREOF
4y 0m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
95%
With Interview (+39.4%)
Low
PTA Risk
Based on 170 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month